ARTICLE | Company News

Amsterdam Molecular to transfer assets, delist

February 18, 2012 1:40 AM UTC

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) said its board unanimously recommended dissolving the company's assets into newly formed uniQure B.V. (Amsterdam, the Netherlands) in a stock deal. Amsterdam said it is facing a "precarious" financial position with cash expected to last until April and the deal is "the only viable way to secure a capital injection." Amsterdam Molecular will delist.

Amsterdam said uniQure will continue to develop Amsterdam's Phase I/II gene therapy AMT-060 for hemophilia B, and preclinical compounds AMT-090 for Parkinson's disease (PD) and AMT-021 for acute intermittent porphyria. uniQure will not invest additional funds to develop discontinued lipoprotein lipase gene therapy Glybera unless it receives a positive decision from regulatory authorities (see BioCentury Extra, Jan. 30). ...